Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Down syndrome newborn screening and treatment protocol for transient myeloproliferative disease
NL-OMON31343Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cytarabine in transient leukemia (TAM) and myeloid leukemia associated with Down syndrome (ML-DS) (3 arms), sponsored by Erasmus MC. Started Jan 2008; status: active, not recruiting.
02
Drugs
cytarabine
03
Conditions
transient leukemia (TAM)myeloid leukemia associated with Down syndrome (ML-DS)
Beyond the preview
Go deeper on NL-OMON31343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31343.